Clujul Medical - Iuliu Haţieganu

Clujul Medical 2006 vol. LXXX - nr. 1
16. JAFFE AB, TORAN- ALLERAND CD, GREENGARD P, GANDY SE.: Estrogen
regulates metabolism of Alzheimer amyloid β precursor protein. J Biol Chem 1994;
269: 13065-13068.
17. PETANCESCA SS, NAGY V, FRAIL D, GANDY S.: Ovariectomy and 17 betaestradiol
modulate the levels of Alzheimer’s amyloid beta peptides in brain. Exp
Gerontol 2000; 35: 1317-1325
18. PAGANINI- HILL A., HENDERSON VW.: Estrogen deficiency and risk ok
Alzheimer’s disease in women. Am J Epidemiol 1994; 140: 256-261 .
The influence of estrogen therapy on the brain: its
implications in the neurodegenerative diseases
FULGA FLORESCU, N.COSTIN
Summary
In the long term, the decrease of post-menopausal estrogen level increases
depression and anxiety, the risk of Alzheimer’s disease and Parkinson, influences the
rate of ischemic strokes.
The studies of estrogen substitution treatment show benefic effects on the
cognitive functions (especially on the memory), but also on motility and psychical state.
The estrogen protects the brain from neuro-degenerescence, inducing the formation of
novo-synapses, favoring the cholinergic transmission, and promoting neural survival.
The estrogen treatment at menopause delays the age related cognitive
alterations, influences the estrogen sensitive neuro-transmitters, regulates brain
vascularization, and protects the brain from oxidating stress.
The detection of the neuroprotective effect of estrogen offers new
pharmaceutical opportunities when it comes to redefine the estrogen substitution
therapy.
Key words: neurotransmitters, neurodegenerescence, estrogen substitution
therapy, cognitive function, motility.
28